Aleksei V. Emelianov has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Digital Remote Monitoring on the Optimization of Guideline-Directed Medical Therapy Titration in Heart Failure With Reduced Ejection Fraction

    by M. V. Kozhevnikova, A. V. Emelianov, E. A. Zheleznykh, N. A. Pavlov, N. V. Khabarova, Yu. N. Belenkov

    Aim   To evaluate the impact of digital remote monitoring on the effectiveness of intensive dose titration for guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) for the achievement of target doses and the reduction of decompensated heart failure rate and all-cause mortality. Materials and methods The study utilized vital sign monitoring via a personal messenger-based questionnaire (chatbot) and weekly therapy optimization recommendations for 6 weeks following hospital discharge. The control group received standard outpatient care. The study is registered at ClinicalTrials.gov (NCT06304753). Between October 27, 2023, and December 27, 2024, 66 HFrEF patients were enrolled and randomized into a remote monitoring (RM) group (n=33) and a standard care (SC) group (n=33). The 6-week observation period was completed by 26 patients in the RM group and all 33 patients in the SC group. Results   The RM group showed a statistically significant increase in the dosages of GDMT and a higher number of patients reaching target doses. In contrast, the SC group showed either no changes in therapy or a decrease in dosages of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor (87.5 [50; 100]% vs. 25 [12.5; 25]%, pConclusion The study confirmed the feasibility, efficacy, and safety of intensive titration of guideline-directed medical therapy for chronic heart failure using remote monitoring.

  • Open Access

    Nano-FTIR identification of functionalization in two-photon oxidized graphene

    by Gour Mohan Das, Eero Hulkko, Aleksei Emelianov, Marc Garriga Santiveri, Pasi Myllyperkiö, Andreas Johansson, Mika Pettersson


  • Open Access

    Six-Month Remote Monitoring of Patients With Chronic Heart Failure Using Messaging Applications on Smartphones

    by Elena Zheleznykh, Anastasia Panova, Aleksei Emelianov, Daria Kutsakina, Andrei Nartov, Valeria Nartova, Nikolay Pavlov, Yuri Belenkov, Maria Kozhevnikova

    Background: Patients with chronic heart failure (HF) require outpatient monitoring after hospital discharge. The ability to use a smartphone with a personal messaging application may help. Objectives: Tis study aimed to investigate the feasibility of remote monitoring and evaluate its impact on treatment adherence and prognosis in patients with HF. Methods: A total of 100 patients were enrolled in the study: 57 patients in the mHealth group and 43 in the control group. The observation period lasted six months. [...] Abstract Background: Patients with chronic heart failure (HF) require outpatient monitoring after hospital discharge. The ability to use a smartphone with a personal messaging application may help. Objectives: Tis study aimed to investigate the feasibility of remote monitoring and evaluate its impact on treatment adherence and prognosis in patients with HF. Methods: A total of 100 patients were enrolled in the study: 57 patients in the mHealth group and 43 in the control group. The observation period lasted six months.


  • Open Access

    The Contribution of Digital Remote Monitoring to Improving the Effectiveness of Treatment in Patients with Chronic Heart Failure with Reduced Ejection Fraction: data after a 6-week follow-up period (Preprint)

    by Maria Kozhevnikova, Aleksei Emelianov, Elena Zheleznykh, Nikolay Pavlov, Natalia Khabarova, Yuri Belenkov

    BACKGROUND The main strategy for the management of heart failure (HF) patients with reduced ejection fraction is guideline-directed medical therapy (GDMT). Remote GDMT optimization using digital monitoring and guideline support appears to be a promising method. Therefore, the Contribution of Digital Remote Monitoring to Improving the Effectiveness of Treatment in Patients with Chronic Heart Failure with Reduced Ejection Fraction (BOT-IMPROVE-HF) was conducted. OBJECTIVE The aim of the study is to assess the effectiveness of rapid titration of GDMT to reach the target doses and reduce the combined endpoint of all-cause mortality and HF decompensation. METHODS This research introduces a multifaceted approach consisting of the following components: vital signs data sharing using a questionnaire via a free mobile messaging tool (chatbot), and weekly digital guideline recommendations to optimize therapy weekly for 6 weeks. RESULTS A total of 66 patients with HF with reduced ejection fraction were randomized between the remote monitoring (RM) group and the usual care (UC) group between 27 October 2023 and 27 December 2024. Thirty-three patients were included in each group. Twenty-six patients in the RM group and all patients in the UC group completed the 6-week follow-up period and were taken for primary endpoint analysis. There was a significant increase in the median dose of GDMT in the RM group, while there were no changes or were down-titrations in the UC group [angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors P < 0.001*); β-blockers (P = 0.0001*); mineralocorticoid receptor antagonists (P = 0.005*)]. The doses of diuretics were significantly reduced in the RM group (P = 0.01*) and did not change in the UC group after 6 weeks (P = 0.9). HF decompensation and mortality rates were higher in the UC group than in the RM group (16 (2 mortality, 14 decompensations) vs 2 (0 mortality, 2 decompensations), P = 0.0003*). No difference was observed between the RM group and the UC group after 6 weeks in systolic blood pressure (P = 0.9), heart rate (P = 0.06), estimated glomerular filtration rate (P = 0.22) and potassium level (P = 0.33). CONCLUSIONS The article shows the results of a 6-week follow-up period. The BOT-IMPROVE-HF trial met its primary outcome and achieved a higher dose of GDMT in the RM group. The intervention was safe, and no treatment complications were registered. CLINICALTRIAL ClinicalTrials.gov NCT06304753

  • Open Access

    Remote monitoring of patients with chronic heart failure: a non-invasive approach

    by Aleksei V. Emelianov, Maria V. Kozhevnikova, Elena A. Zheleznykh, Anastasia L. Panova, Elena V. Privalova, Yuri N. Belenkov, Vladimirovich

    Remote monitoring of patients, including those with chronic heart failure, has been actively used in recent years. Unlike invasive methods, non-invasive methods are not associated with surgical risks and offer a wide range of patient management options such as telemonitoring, virtual visits, emergency department pre-triage, in-hospital telemedicine, telemedicine rehabilitation, psychological support, etc. Previously, remote monitoring required a multidisciplinary medical team to ensure high efficiency, and attempts to use advanced technology to reduce human involvement were often unsuccessful. However, all electronic and telemedicine technologies in healthcare have been dramatically transformed by the COVID-19 pandemic. There is currently a wide variety of remote monitoring methods and technologies. But it is still impossible to clearly assess their effectiveness due to a lack of common standards, inadequate legislation, and regional, social, and economic differences in the availability of these technologies. However, in 2021, remote monitoring was included in the European Society of Cardiology clinical guidelines for the diagnosis and management of acute and chronic heart failure (IIb). This review describes the history of modern remote monitoring methods and the problems they are designed to solve in order to improve outpatient health monitoring for patients with chronic heart failure.


  • Open Access

    Relationship of Acylcarnitines to Myocardial Ischemic Remodeling and Clinical Manifestations in Chronic Heart Failure

    by Yuri N. Belenkov, Anton A. Ageev, Maria V. Kozhevnikova, Natalia V. Khabarova, Anastasia V. Krivova, Ekaterina O. Korobkova, Ludmila V. Popova, Alexey V. Emelyanov, Svetlana A. Appolonova, Natalia E. Moskaleva, et al.

    Background: Progressive myocardial remodeling (MR) in chronic heart failure (CHF) leads to aggravation of systolic dysfunction (SD) and clinical manifestations. Identification of metabolomic markers of these processes may help in the search for new therapeutic approaches aimed at achieving reversibility of MR and improving prognosis in patients with CHF. Methods: To determine the relationship between plasma acylcarnitine (ACs) levels, MR parameters and clinical characteristics, in patients with CHF of ischemic etiology (n = 79) and patients with coronary heart disease CHD (n = 19) targeted analysis of 30 ACs was performed by flow injection analysis mass spectrometry. Results: Significant differences between cohorts were found for the levels of 11 ACs. Significant positive correlations (r > 0.3) between the medium- and long-chain ACs (MCACs and LCACs) and symptoms (CHF NYHA functional class (FC); r = 0.31−0.39; p < 0.05); negative correlation (r = −0.31−0.34; p < 0.05) between C5-OH and FC was revealed. Positive correlations of MCACs and LCACs (r = 0.31−0.48; p < 0.05) with the left atrium size and volume, the right atrium volume, right ventricle, and the inferior vena cava sizes, as well as the pulmonary artery systolic pressure level were shown. A negative correlation between C18:1 and left ventricular ejection fraction (r = −0.31; p < 0.05) was found. However, a decrease in levels compared to referent values of ACs with medium and long chain lengths was 50% of the CHF-CHD cohort. Carnitine deficiency was found in 6% and acylcarnitine deficiency in 3% of all patients with chronic heart disease. Conclusions: ACs may be used in assessing the severity of the clinical manifestations and MR. ACs are an important locus to study in terms of altered metabolic pathways in patients with CHF of ischemic etiology and SD. Further larger prospective trials are warranted and needed to determine the potential benefits to treat patients with CV diseases with aberrate AC levels.


  • ‘Last mile’ Problem in Remote Patient Monitoring at Home: the Use of Instant Messaging Applications

    by Elena A. Zheleznykh, Aleksei V. Emelianov, Maria V. Kozhevnikova, Vita Y. Zektser, Elena V. Privalova, Yuri N. Belenkov

    Telemedicine is one of the most evolving areas of healthcare that meets the needs of the patient of modern times: mobile accessibility, personalized approach, and rapid service delivery. However, no matter how good the telemonitoring system is, the patient will tend not to use it if it is excessively expensive, hard to apprehend, or if it hardly interferes with everyday life (the ‘last mile” problem). In this study, we investigate how instant messaging (1M) applications can help overcome the ‘last mile” problem. A simple experimental tool was developed and patented, which enables the medical professionals to set the self-assessment questionnaire automatically sent through 1M to the patients daily at a given time. The results are collected and analyzed in the cloud, where the ‘traffic lights” colored flags are set, with a red-colored flag indicating an urge of immediate reaction. To prove the eligibility of the use of 1M, we asked 25 patients with chronic heart failure to receive and answer the questionnaire (6 or 7 questions on a person's health condition with predefined answers, depending on the day of the week) for 3 months. The adherence was considered positive if the questionnaire was filled out daily (24 hours were given to finish the task) for the whole period of observation, or negative if there was at least one missed or incomplete response. Out of 25 patients, 17 showed positive adherence (68%). Thus, we can conclude about the viability of such an interface of patient interaction with telemedicine care and the high potential of using 1M to solve the ‘last mile” problem in telemedical continuous monitoring of patients at home.

  • Open Access

    Quality of life and adherence to therapy in patients with chronic heart failure who were remotely monitored by chatbot compared to the standard follow-up group for 3 months

    by Aleksei V. Emelianov, Elena A. Zheleznykh, Maria V. Kozhevnikova, Anton A. Ageev, Vita Y. Zektser, Yuri N. Belenkov

    BACKGROUND: Chronic heart failure (CHF) is one of the leading causes of death. Telemedicine and remote monitoring (RM) are a way to increase life expectancy and quality of life in patients with CHF. Methods based on messengers familiar to patients promote adherence and do not require additional training. AIM: To compare quality of life and adherence to therapy in patients with CHF who were on RM using a chatbot compared to the standard follow-up (SFU) group for 3 months. METHODS: Patients with CHF on optimal drug therapy discharged from the hospital were included in the study. Comparison groups were formed according to the method of observation, particularly, RM and SFU. A chatbot was set up for patients in the RM group. Monitoring was done using a seven-question survey sent daily. The signs of decompensation (red flags [RF]) were increased edema, dyspnea, body weight 2 kg per week, and changes in individual parameters of heart rate and blood pressure. If a RF was detected, telephone contact was made, and the therapy was corrected if necessary. Quality of life was assessed according to the Minnesota Quality of Life Questionnaire for patients with CHF (highest, 0 points; lowest, 105 points), and adherence was assessed using the Adherence Scale of the National Society for Evidence-based Pharmacotherapy. RESULTS: A total of 60 patients were included in the study; 37 patients completed a 3-month follow-up. The RM group (n=17, 13 men, 76.5%; median age 61 [51; 62]) and comparison group (n=20, 14 men, 70%; mean age 64.98.9) were comparable according to the functional class (New York Heart Association), but differed in ejection fraction (42.813% versus 53.210.4% [p 0.05]). Adherence to the chat-bot was 67.2%. Adherence to therapy was not significantly different between the RM and SFU groups accounting for (17 [100%]) and (18 [90%], respectively, (p=0.62). In the RM group, RF was detected in 7 (41%) patients. Only one patient required correction of therapy. Patients in the RM group required no referral to a medical facility, whereas 2 patients in the SFU group required medical care. Quality of life was statistically significantly higher in the RM group, reaching 28.713.9 points compared to 37.717.9 points in the SFU group (p=0.04). CONCLUSIONS: After 3 months, patients in the RM group were committed to the chatbot, with adherence to therapy comparable to the SFU group. Quality of life was statistically significantly higher in the RM group. Patients in the RM group did not go to medical facilities, in contrast to the SFU group. The limitations of the study were the small sample size and short follow-up period. The results require further research to obtain additional data.


  • Open Access

    Assesment of Markers of Endothelial Dysfunction and Myocardial Stress in Patients with Hypertrophic Cardyomyopathy

    by F. M. Bogatyreva, V. Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, D. A. Yatsenko, А. V. Emelianov, A. S. Lishuta, N. V. Khabarova, E. V. Privalova, Yu. N. Belenkov

    Aim. To study the level of serum biomarkers of endothelial dysfunction and myocardial stress in patients with various types of hypertrophic cardiomyopathy (HCM).Material and Methods. 48 patients with hypertrophic cardiomyopathy (27 men and 21 women) were examined, the mean age was 54±13 years. The patients were divided into two groups according to the course options: group 1 - symptomatic stable course (n=14); group 2 - progressive course of symptomatic HCM (n=34). In accordance with the assigned tasks, all patients underwent determination of biological markers of neurohumoral systems in blood serum using immunofluorescence assay analysis: N-terminal fragment of brain natriuretic peptide (NT-proBNP), von Willebrand factor (vWF), endothelin-1, E-selectin with subsequent evaluation and correlation of results with clinical and instrumental characteristics of patients. When performing echocardiography following parameters were assessed: dimensions of the heart chambers, the thickness of the interventricular septum, the thickness of the posterior wall of the left ventricle (LV), LV mass, LV mass index, the ratio between LV filling in diastole (peak E) and atrial systole (peak A)-(E/A), relative myocardial thickness index, left atrial volume index.Results. Both groups showed increased levels of NT-proBNP and endothelin-1. E-selectin and vonWillebrand factor remained within the normal range. There was no statistically significant intergroup difference. There was a correlation between the level of the index of the relative myocardial thickness and the level of NT-proBNP (r=0.30; p=0.04). A correlation was found between the level of the vWF marker and the left atrial volume index (r=0.32; p=0.04). When assessing the association of indicators of intracardiac hemodynamics with other markers (E-selectin and endothelin-1, no statistically significant relationships were found.Conclusion. In the course of the research, it was found that the high activity of endothelin-1 and NT-proBNP reflects endothelial dysfunction and myocardial stress in patients with HCM, especially in patients with a progressive variant of HCM. However, we did not find any changes in the levels of E-selectin and von Willebrand factor, as well as their intergroup differences. These results require additional studies to assess endothelial dysfunction in patients with HCM.